One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?

Leukemia Research

Volumn 30, Issue 12, 2006, Pages 1563-1568

  Schmitt, Christina ^a   Grundt, Alexander ^a   Buchholtz, Christian ^a   Scheuer, Lars ^a   Benner, Axel ^b   Hensel, Manfred ^a   Ho, Anthony D ^a   Leo, Eugen ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Follicular lymphoma; Molecular monitoring; Rituximab; RQ PCR; t(14 ; 18)

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN HEAVY CHAIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MALE; MOLECULAR HYBRIDIZATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GENES, BCL-2; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; INFUSIONS, INTRAVENOUS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PREDNISONE; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VINCRISTINE;

EID: 33750015718     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.01.014     Document Type: Article

References (10)

1. Mandigers C.M., Meijerink J.P., Mensink E.J., Tonnissen E.L., Hebeda K.M., Bogman M.J., et al. Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma. Blood 98 (2001) 940-944
2. Rambaldi A., Lazzari M., Manzoni C., Carlotti E., Arcaini L., Baccarani M., et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 99 (2002) 856-862
3. Nelson E.L., Li X., Hsu F.J., Kwak L.W., Levy R., Clayberger C., et al. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 88 (1996) 580-589
4. Colombat P., Salles G., Brousse N., Eftekhari P., Soubeyran P., Delwail V., et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97 (2001) 101-106
5. Czuczman M.S., Grillo-Lopez A.J., White C.A., Saleh M., Gordon L., LoBuglio A.F., et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17 (1999) 268-276
6. Dyer M.J., Fischer P., Nacheva E., Labastide W., and Karpas A. A new human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t(14;18) and t(4;11) chromosomal translocations. Blood 75 (1990) 709-714
7. van der Velden V.H., Hochhaus A., Cazzaniga G., Szczepanski T., Gabert J., and van Dongen J.J. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17 (2003) 1013-1034
8. Agresti A., and Coull B.A. Approximate is better than "exact" for interval estimation of binomial proportions. Am Statis 52 (1998) 119-126
9. Ghielmini M., Schmitz S.F., Cogliatti S.B., Pichert G., Hummerjohann J., Waltzer U., et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 103 (2004) 4416-4423
10. Vose J.M., Link B.K., Grossbard M.L., Czuczman M., Grillo-Lopez A., and Gilman P. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19 (2001) 389-397